Aphria fallout: 5 takeaways on the report that sent this cannabis stock plunging

The blows to Aphria’s stock continued Wednesday as the Canadian cannabis giant’s share price tumbled in the wake of a scathing short-seller report.

Aphria’s stock (Nasdaq: APHA) closed Wednesday at $4.51 – down more than 25% for the day.

The company has been on the defensive since Monday, refuting claims lobbed by short sellers Quintessential Capital Management and Hindenburg Research that Aphria’s management is a part of a shell game controlled by insiders raiding company coffers to line their own pockets.

Aphria, in a statement issued Monday, called the allegations “malicious.”

But some of the concerns raised by the short-seller report could have broader implications for the rapidly growing cannabis industry, analysts and observers say.

“This could be the proverbial straw that breaks the camel’s back,” said Chris Damas, editor of BCMI Cannabis Report.

“The overvaluation case (for the Canadian licensed producers) could finally be resonating with investors, and it takes something like this to break down the floodgates.”

As the fallout evolves, here are five key takeaways for investors and cannabis operators to consider:

1. Not Aphria’s first red flag

This isn’t the initial harsh report issued by Hindenburg on Aphria.

In March, the firm released a report claiming it uncovered “rampant red flags” in its review of Aphria’s acquisition of Nuuvera for 826 million Canadian dollars ($669 million at that time).

The deal raised eyebrows among industry observers after it was reported Aphria’s chief financial officer and six directors owned shares of Nuuvera before the deal. Those details had not been previously disclosed to shareholders.

A month later, Aphria adopted new guidelines for its top leadership on investing in outside companies.

In the most recent report, the short sellers claim that Aphria overpaid for assets in the Caribbean and Latin America that were secretly controlled by “insiders” and are “largely worthless.”

The report’s researchers claim they performed “extensive on-the-ground” due diligence on recently acquired properties in Jamaica, Colombia and Argentina and found the deals to be “vastly inflated or outright fabrications.”

In one example, the report alleges that assets acquired in Jamaica for CA$145 million ($108 million) were “an abandoned building that was sold off by the bank earlier this year.”

Officials with Quintessential Capital Management and Hindenburg Research could not be reached for comment.

To the knowledge of Marijuana Business Daily, the claims detailed in the reports on Aphria have not been independently verified.

2. Bigger than Aphria

The accusations could have broader implications for the industry and call into question just how much due diligence occurs as cannabis companies embark on their rapid expansions, said Andrew Kessner, an analyst with New York-based investment advising firm William O’Neil.

“Things have been moving so quickly in this space that a lot of companies have gotten a pass as far as what they’ve been spending their money on and why,” he said. “I think investors are starting to wise up and ask, ‘What’s really under the hood?’

“Are these executives really being good stewards of investor capital or are they inflating their company’s position to bring up valuations and do another round of funding?”

Damas agreed.

“It’s this sort of thing that could be the crack in the dike – so to speak,” he said. “It’s going to have ramifications for the whole industry.

“Other people are going to start taking a look at those assets that are far and away and wonder if they’re really worth what management is paying.”

3. Reassessing international plays

Aphria’s stock selloff could also signal just how critically investors view the international footprints of Canada’s larger cannabis producers, Kessner said.

“These companies have used the Canadian (capital) markets as a launching pad to raise money based on their plans to grow internationally,” he said.

“If that growth story – of being a global player – gets shot down, then their valuation begins to make no sense.”

Analysts at both GMP Securities and Bank of Nova Scotia moved their ratings for Aphria to “under review” after the short-seller report.

“We believe that management’s credibility may have been impacted by the allegations raised in this report,” GMP analysts wrote in a note to investors. “It is unclear at this point how the company will re-establish trust with investors.”

4. Assessing Aphria’s response

Since the short-seller report went public Monday, Aphria has issued two public responses.

In one statement, the company called the allegations “malicious,” adding that “by their own admission, Hindenburg Research ‘… stands to realize significant gains in the event that the price of any stock covered herein declines.’”

Officials with Aphria could not be reached for comment Wednesday.

Whether Aphria’s response will resonate with investors remains to be seen, Kessner said.

“Any stock is subject to short sellers. If the case being made by a short seller doesn’t have any merit, then that will come out,” he added.

“But simply saying, ‘These are short sellers and they’re just doing it to make money’ doesn’t mean much for anyone.”

5. Regulators taking notice

Meanwhile, Canada’s stock market regulator has issued a warning to publicly traded companies in emerging industries such as cannabis against “problematic promotional activities” aimed at artificially increasing share price.

The notice – issued by the Canada Securities Administrators (CSA) – did not single out any cannabis companies, but experts say many of the practices the memo warns against have been observed in the industry.

Jason Zandberg, analyst at PI Financial in Vancouver, British Columbia, said unscrupulous actors making unsubstantiated claims to benefit stock prices is part of any rising equity market.

“There is no doubt that cannabis has been one of those rising-tide moments and there have been many misleading promoters abusing the widespread investor enthusiasm,” he said.

“I hope the (CSA) does more than just release notices to limit these practices.”

International analyst Alfredo Pascual contributed to this report.

Lisa Bernard-Kuhn can be reached at [email protected]

Matt Lamers can be reached at [email protected]

3 comments on “Aphria fallout: 5 takeaways on the report that sent this cannabis stock plunging
  1. George Bianchini on

    ” management is a part of a shell game controlled by insiders raiding company coffers to line their own pockets.”

    CBIS is another one. It’s CEO Raymond Dabney. For Mr. Dabney, the lawsuit comes seven years after the U.S. Securities and Exchange Commission won a $193,337 (U.S.) decision against him for manipulating a pink sheets company called Strategy X Inc. The SEC accused him and others of issuing false and misleading news releases touting the stock in 2005. The group also issued 60 million free-trading shares in repeated illegal offerings. That penalty came on top of a ban that he received from the B.C. Securities Commission on Nov. 21, 2005. The ban, which lasted five years, was to settle a case in which the BCSC said that he issued misleading news releases about a company called Xraymedia Inc.

    Mr. Dabney’s most recent venture, Cannabis Science , (CBIS) an active trader on the OTC Pink, https://www.pressreader.com/canada/stockwatch-daily/20180105/281500751639019
    By the comments on the stock board it appears that Mr. Dabney is at it again with CBIS. Be careful what you buy out there, there are many scams taking advantage of well-meaning investors.

    Reply
  2. Michelle Miller on

    Thank you for letting me find this article, because being shareholders of “CBIS aka Cannabis Science Inc Co” and having bought into them over a year ago purchased on 12/17 they were one of the first cannabis company I researched and did my “Due Diligence” for us and and granted was happy knowing this was going to be a new industry (for the stock market & for people) to try to get a so so valuation on them, everything Mr. Dabney had out on their website and their SEC filings, and prospectus all looked good as well as what they were wanting to become and create for the benefits of people like myself with chronic pain, anxiety,more so for these children with epilepsy ,seizures, etc. But when we knew something wasn’t right with what Mr. Dabney was saying was because #1 starting noticing for the last several months there was no updates on our brokerage’s page (Fidelity) and so I started emailing them asking what’s going on with the company? Also called and emailed about the loyalty gifts shares we were suppose to have gotten over a year ago? But just like some of the other cannabis co’s we’re finding are doing the same and I’ve had to reach out to them and blatantly ask what is going on? As well as letting them know that we want to know why is it that they’ve made millions over millions in their last quarter(s) but theres no revenue coming back to us the shareholders, I mean hell even a couple of pennies you know? Also that we’re tried of us shareholders having to foot the bill so to speak because when they go under and of course don’t say anything to give you a heads up but we get the raw end of the deal!! They need to be held accountable for what their not telling us, because we little people out here are definitely tried of the lies of the stock markets and all the money we put into these companies to believe in what they tell us only to look forward to our investment to be taken away . Heck and we not even getting a kiss while we’re being screwed!! Thanks for the articles, Michelle & David Miller

    Reply
  3. Simon Chapman on

    LGC Capital have raised millions of dollars on the back of an investor deck containing outright lies about their claimed South African cannabis licenses and the credentials of their JV partners. Co-chairman, David Lenigas has already been hounded out of London’s AIM market and has now found a new audience to tap in Canada. He keeps touting LGC’s global assets but the truth is that the company owns almost nothing apart from a small investment in Australia. Deals never seem to close; so-called “binding” agreements are varied without explanation. The CEO, John McMullen, tweeted last year that the company did not need to raise any more cash for its planned investment program – and then announced a big cash raise for that purpose just five days later. There are no revenues and precious little in the way of tangible assets. Complaints have been lodged with the Canadian regulators but nothing seems to happen. Meanwhile, the company’s share price has plummeted from a pumped-up $1 to $0.10 and the latest (unclosed) deal has just been announced – with an Italian cannabis retailer whose CBD products allegedly exceed the permitted THC content.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *